Trials / Conditions / Refractory Urothelial Carcinoma
Refractory Urothelial Carcinoma
3 registered clinical trials studyying Refractory Urothelial Carcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Active Not Recruiting | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastat NCT04579224 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced NCT04856189 | Mamta Parikh | Phase 1 / Phase 2 |